Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC

Dr Rini on a Biomarker Analysis of KEYNOTE-426 Using Subtype Clustering RCCПодробнее

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCCПодробнее

Dr. Rini on Pembrolizumab Plus Axitinib in RCCПодробнее

Dr. Rini Describes Hypertension as a Biomarker in RCCПодробнее

Dr. Rini on Challenges With Biomarkers in RCCПодробнее

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCCПодробнее

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCCПодробнее

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCCПодробнее

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCCПодробнее

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCCПодробнее

Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivoПодробнее

Axitinib plus pembrolizumab in advanced RCCПодробнее

Dr. Rini Discusses the VEGF Targeted Agent AxitinibПодробнее

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCCПодробнее

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCCПодробнее

Dr. Rini Explains the Axitinib Integration ProcessПодробнее

Promising results for axitinib and pembrolizumab in advanced renal cell cancerПодробнее

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaПодробнее

Pembrolizumab monotherapy and pembro-axitinib for RCCПодробнее